Published in J Clin Oncol on January 01, 2008
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol (2014) 1.58
Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol (2010) 1.52
Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol (2010) 1.49
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs (2010) 1.33
Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol (2012) 1.32
Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer (2011) 1.27
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol (2009) 1.21
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer (2010) 1.19
Retracted Metastatic collecting duct carcinoma of the kidney treated with sunitinib. World J Surg Oncol (2011) 1.15
Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res (2009) 1.07
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J (2015) 1.03
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer (2009) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol (2012) 1.02
Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol (2012) 1.00
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist (2013) 0.99
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol (2011) 0.98
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res (2010) 0.97
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Metachronous contralateral testicular and bilateral adrenal metastasis of chromophobe renal cell carcinoma: a case report and review of the literature. J Zhejiang Univ Sci B (2010) 0.93
Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer (2014) 0.93
Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biol Med (2014) 0.93
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol (2008) 0.93
Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can Urol Assoc J (2012) 0.92
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One (2010) 0.92
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am (2011) 0.90
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology (2011) 0.90
Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncol Lett (2012) 0.89
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol (2016) 0.89
Renal collision tumour of papillary cell carcinoma and chromophobe cell carcinoma with sarcomatoid transformation: A case report and review of the literature. Can Urol Assoc J (2014) 0.88
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer (2012) 0.88
Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol (2009) 0.87
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol (2009) 0.86
Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med (2013) 0.86
Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol (2014) 0.85
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
Saudi Oncology Society clinical management guidelines for renal cell carcinoma. Urol Ann (2011) 0.85
The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. J Cancer Res Clin Oncol (2009) 0.84
Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol (2009) 0.84
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma. Am J Pathol (2011) 0.84
A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases J (2009) 0.84
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol (2015) 0.83
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Rep (2009) 0.83
Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol (2013) 0.83
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J Clin Oncol (2008) 0.83
Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int (2014) 0.82
Targeting the mTOR pathway in Chromophobe Kidney Cancer. J Cancer (2012) 0.82
Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis (2014) 0.82
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol (2012) 0.81
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol (2008) 0.81
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol (2013) 0.81
Chromophobe renal cell carcinoma with and without sarcomatoid change: a clinicopathological, comparative genomic hybridization, and whole-exome sequencing study. Am J Transl Res (2015) 0.80
The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology (2013) 0.80
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One (2013) 0.80
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat (2015) 0.79
Sorafenib in the management of metastatic renal cell carcinoma. Curr Oncol (2009) 0.79
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Can Urol Assoc J (2013) 0.79
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. Mol Cancer (2014) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
The ineligible patient: how to treat patients not included in clinical studies. World J Urol (2013) 0.78
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? Oncologist (2012) 0.78
Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. Can Urol Assoc J (2015) 0.78
Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp Nephrol (2011) 0.77
Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2016) 0.77
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol (2011) 0.77
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol (2013) 0.77
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Indian J Urol (2014) 0.76
Indications for biopsy and the current status of focal therapy for renal tumours. Transl Androl Urol (2015) 0.75
Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol (2008) 0.75
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother (2012) 0.75
Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med (2015) 0.75
Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med (2017) 0.75
Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis. Oncol Lett (2010) 0.75
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Oncologist (2016) 0.75
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report. J Med Case Rep (2012) 0.75
Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma. Springerplus (2015) 0.75
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? Cancer (2016) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann (2014) 0.75
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Urol Ann (2016) 0.75
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol (2011) 0.75
Occult infiltrating bi-ventricular papillary renal cell carcinoma metastasis found during coronary artery bypass graft surgery. Can Urol Assoc J (2012) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol (2017) 0.75
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. Int J Clin Oncol (2010) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Renal cell carcinoma. Lancet (2009) 6.92
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Renal mass biopsy--a renaissance? J Urol (2007) 3.12
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol (2010) 2.44
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
Histone H2A.Z cooperates with RNAi and heterochromatin factors to suppress antisense RNAs. Nature (2009) 2.19
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol (2011) 2.17
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Structural and thermodynamic properties of selective ion binding in a K+ channel. PLoS Biol (2007) 2.10
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol (2009) 2.10